Factive's North American Rights Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Asset Purch.
- Financing Rounds
-
3
Factive's North American Rights General Information
Description
North American product rights for an antibiotic product. The asset is used for the treatment of community-acquired pneumonia of mild to moderate severity and acute bacterial exacerbation of chronic bronchitis.
Contact Information
Corporate Office
- United States
Corporate Office
- United States
Factive's North American Rights Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Factive's North American Rights Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Factive's North American Rights FAQs
-
Where is Factive's North American Rights headquartered?
Factive's North American Rights is headquartered in .
-
What industry is Factive's North American Rights in?
Factive's North American Rights’s primary industry is Buildings and Property.
-
Is Factive's North American Rights a private or public company?
Factive's North American Rights is a Private company.
-
What is Factive's North American Rights’s current revenue?
The current revenue for Factive's North American Rights is .
-
Who are Factive's North American Rights’s investors?
Chiesi USA, LG Life Sciences (INDIA), and Oscient Pharmaceuticals have invested in Factive's North American Rights.
-
When was Factive's North American Rights acquired?
Factive's North American Rights was acquired on 07-Mar-2012.
-
Who acquired Factive's North American Rights?
Factive's North American Rights was acquired by Merus Labs International.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
